Myelofibrosis

Diagnosis and management of myeloproliferative neoplasm.

Reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP (General Practitioner)

Last reviewed: 21 October 2025

Haematology

Clinical Guidelines

NICE guideline [TA386]: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with primary myelofibrosis

NICE guideline [TA957]: Momelotinib for treating myelofibrosis-related splenomegaly or symptoms

ASH Clinical Practice Guidelines: Myelofibrosis

Consensus-Based Best Practice Recommendations for Myelofibrosis Management in Routine Clinical Practice

International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Consensus Statement: Revised response criteria for myelofibrosis

Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group

NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms (includes Myelofibrosis)

Philadelphia chromosome-negative classical myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up